source
- BMS CAR-T therapy arlo-cel meets primary endpoint in pivotal multiple myeloma trialBristol Myers Squibb reported that its GPRC5D-directed CAR-T cell therapy, arlo-cel, achieved the primary endpoint in the pivotal Quintessential trial for multiple myeloma. The study enrolled pati…
- Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale productionAfter mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly. The recent clinical…